Het gebruik van 18F-FDG PET/CT ter evaluatie van multipel myeloom

Abstract

The use of 18F-FDG PET/CT to evaluate patients with multiple myeloma. Detection of bone lesions are important to diagnose multiple myeloma. In this study we investigate the role of an 18F-FDG PET/CT exam. Fifteen newly diagnosed multiple myeloma patients were included in this retrospective study. A 18F-FDG PET/CT was performed at diagnosis and after induction therapy. The response of a treatment is examined by semi-quantitative parameters (standardised 18F-FDG uptake values) and volumetric parameters (metabolic tumor volume and total lesion glycolysis). The aim of this study is to evaluate the use of these parameters for response evaluation and risk assessment in multiple myeloma. The prognostic value of an increased metabolic activity of the spleen is also examined. All semi-quantitative and volumetric parameters in this study are useful for response evaluation. Lower values of maximum or mean standardized uptake values (SUVmax, SUVmean) and total lesion glycolysis at diagnosis are prognostic favourable. We could not prove prognostic relevance for a spleen to liver ratio. Due to the small study population, all these results have to be confirmed in a larger patient cohort. 18F-FDG PET/CT is a reliable technique for response evaluation and risk stratification in multiple myeloma. In the future semi-quantitative and volumetric parameters will probably be incorporated in the risk classification systems of multiple myeloma patients.